Galectin Therapeutics Inc. Forecasted to Earn Q1 2017 Earnings of ($0.15) Per Share (GALT)
Galectin Therapeutics Inc. (NASDAQ:GALT) – Research analysts at Roth Capital raised their Q1 2017 EPS estimates for shares of Galectin Therapeutics in a research report issued on Wednesday. Roth Capital analyst S. Yaniv now expects that the brokerage will post earnings per share of ($0.15) for the quarter, up from their prior forecast of ($0.17). Roth Capital has a “Sell” rating and a $0.75 price target on the stock. Roth Capital also issued estimates for Galectin Therapeutics’ Q2 2017 earnings at ($0.16) EPS, Q3 2017 earnings at ($0.12) EPS, Q4 2017 earnings at ($0.09) EPS, FY2017 earnings at ($0.51) EPS, FY2018 earnings at ($0.18) EPS, FY2019 earnings at ($0.20) EPS and FY2020 earnings at ($0.19) EPS.
A number of other analysts have also commented on GALT. Zacks Investment Research raised Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 19th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Galectin Therapeutics in a research report on Thursday, August 4th. Finally, FBR & Co reaffirmed a “buy” rating and issued a $12.00 target price on shares of Galectin Therapeutics in a research report on Thursday, August 11th.
Shares of Galectin Therapeutics (NASDAQ:GALT) opened at 1.13 on Friday. The stock’s 50 day moving average price is $1.86 and its 200 day moving average price is $1.60. Galectin Therapeutics has a one year low of $1.08 and a one year high of $3.25. The firm’s market cap is $33.09 million.
Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.04.
A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Fund Advisors increased its position in Galectin Therapeutics by 33.8% in the second quarter. BlackRock Fund Advisors now owns 78,955 shares of the company’s stock worth $116,000 after buying an additional 19,967 shares during the period. Advisor Group Inc. bought a new position in Galectin Therapeutics during the second quarter worth about $584,000. Finally, Vanguard Group Inc. increased its position in Galectin Therapeutics by 0.4% in the second quarter. Vanguard Group Inc. now owns 606,537 shares of the company’s stock worth $892,000 after buying an additional 2,490 shares during the period. Institutional investors and hedge funds own 11.69% of the company’s stock.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Stock Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related stocks with our FREE daily email newsletter.